Abstracts tagged "RORγt antagonist"

Abstract Number: 2424 • 2019 ACR/ARP Annual Meeting
RORγt Antagonist Attenuates Experimental Sialadenitis Like Sjögren’s Syndrome via Inhibition of CD25 Expression on CD4+ T Cells
Yuko Ono¹, Hiroto Tsuboi ², Masafumi Moriyama ³, Hiroyuki Takahashi ², Fumika Honda ², Saori Abe ², Yuya Kondo ², Isao Matsumoto ², Seiji Nakamura ⁴ and Takayuki Sumida ², ¹Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Section of Oral and Maxillofacial Oncology, Division of Maxillofacial Diagnostic and Surgical Science, Faculty of Dental Science, Kyushu University, Tsukuba, Japan, ²Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ³Section of Oral and Maxillofacial Oncology, Division of Maxillofacial Diagnostic and Surgical Science, Faculty of Dental Science, Kyusyu University, Fukuoka, Japan, ⁴Section of Oral and Maxillofacial Oncology, Division of Maxillofacial Diagnostic and Surgical Science, Faculty of Dental Science, Kyusyu University, Fukuoka
Background/Purpose: Our previous study demonstrated that T cells specific RORγt transgenic-mice under human CD2 promoter (RORγt-Tg mice) developed severe spontaneous sialadenitis like Sjögren’s syndrome (SS)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].